{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:54:17Z","timestamp":1789044857479,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":345,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Treatment"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Beyond initial antiretroviral therapy (ART), bictegravir\/emtricitabine\/tenofovir alafenamide 50\/200\/25\u2009mg\u2009(B\/F\/TAF) has been evaluated as an option for the continuation of treatment for virologically suppressed individuals who switch from other regimens. While treatment\u2010emergent resistance to bictegravir has not been observed in clinical trials, rare case reports have described resistance development during B\/F\/TAF therapy, typically in the context of suboptimal adherence. Its favourable safety profile, minimal drug\u2013drug interactions and proven virological efficacy suggest that virologically suppressed individuals may benefit from switching to B\/F\/TAF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Descriptive, retrospective, observational study of adults with HIV infection receiving effective non\u2010INSTI (integrase strand transfer inhibitors)\u2010based ART who switched to a B\/F\/TAF, but not all were suppressed. We compared individuals\u2019 viral loads, CD4+ lymphocyte counts, glomerular filtration rates, and lipid profiles before the switch and after 24\u2009weeks of B\/F\/TAF. Safety was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy\u2010nine individuals switched from non\u2010INSTI\u2010based therapies to B\/F\/TAF. At 24\u2009weeks after the switch, HIV\u20101 RNA\u2009&lt;\u200950\u2009copies\/mL was reported in 96.1% and 92.4% of participants per protocol and intention\u2010to\u2010treat analysis, respectively, compared to 81.0% at baseline. This represents a 15.1% increase in virologic suppression (viral load\u2009&lt;\u200950\u2009copies\/mL) compared to baseline. No significant changes were detected in the CD4+ lymphocyte count, glomerular filtration rate, or lipid profile. Adverse events (AEs) were reported in 5.1% of patients. Three patients discontinued treatment due to AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study suggest that patients can switch to B\/F\/TAF from non\u2010INSTI\u2010based therapies without compromising the effectiveness or safety of ART.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/arat\/8818830","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:06:22Z","timestamp":1765551982000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV\u2010Infected Patients"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1637-8387","authenticated-orcid":false,"given":"Fernando","family":"P\u00e9rez-Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1939-4295","authenticated-orcid":false,"given":"Francisco","family":"Jover-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5408-281X","authenticated-orcid":false,"given":"Elisabet","family":"Delgado-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-9350","authenticated-orcid":false,"given":"Jorge","family":"Peris-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-1888","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Bernab\u00e9u-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"e_1_2_14_1_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120"},{"key":"e_1_2_14_2_2","article-title":"ITS, Hepatitis Virales y Tuberculosis Del Ministerio de Sanidad. Documento de Consenso Respecto al Tratamiento Antirretroviral en Adultos Infectados Por el Virus de la Inmunodeficiencia Humana","author":"Panel de Expertos de GeSIDA y Divisi\u00f3n de Control de VIH","year":"2025","journal-title":"GeSIDA-Actualizaci\u00f3n enero"},{"key":"e_1_2_14_3_2","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2025"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"key":"e_1_2_14_9_2","article-title":"Outcomes 48 Weeks After Switching From DTG\/ABC\/3TC or DTG+F\/TAF to B\/F\/TAF","volume":"22","author":"Pozniak A.","year":"2021","journal-title":"HIV Medicine"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003865"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002873"},{"key":"e_1_2_14_12_2","unstructured":"Guti\u00e9rrez-LorenzoM. Rubio-CalvoD. andUrda-RomachoJ. Effectiveness Safety and Economic Impact of the Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Regimen in Real Clinical Practice Cohort of HIV-1 Infected Adult Patients Revista Espa\u00f1ola de Quimioterapia."},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1055"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000027330"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010076"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231168852"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae138"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593"}],"container-title":["AIDS Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/arat\/8818830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/arat\/8818830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/arat\/8818830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:39:04Z","timestamp":1773009544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/arat\/8818830"}},"subtitle":[],"editor":[{"given":"Simone","family":"Carradori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/arat\/8818830"],"URL":"https:\/\/doi.org\/10.1155\/arat\/8818830","archive":["Portico"],"relation":{},"ISSN":["2090-1240","2090-1259"],"issn-type":[{"value":"2090-1240","type":"print"},{"value":"2090-1259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8818830"}}